FLOXIN OTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FLOXIN OTIC (FLOXIN OTIC).
Ofloxacin, a fluoroquinolone, inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription.
| Metabolism | Ofloxacin undergoes minimal hepatic metabolism; small amounts are metabolized via glucuronidation. The drug is primarily excreted unchanged in urine after systemic absorption; however, otic administration results in negligible systemic concentrations. |
| Excretion | Primarily excreted unchanged in urine via glomerular filtration and tubular secretion (70-80%); non-renal elimination (hepatic metabolism and biliary secretion) accounts for 20-30%. |
| Half-life | 6-8 hours in adults with normal renal function; prolonged to 30-50 hours in severe renal impairment (CrCl <20 mL/min). |
| Protein binding | 20-30% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 2.5-3.0 L/kg; indicates extensive tissue penetration. |
| Bioavailability | Otic: negligible systemic absorption; oral: 90-98%. |
| Onset of Action | For otic use: symptomatic relief within 24-48 hours. |
| Duration of Action | Twice-daily dosing maintains therapeutic concentrations; clinical improvement typically within 3-5 days. |
| Molecular Weight | 361.37 |
Instill 5 drops (0.5 mL) into affected ear(s) twice daily for 10-14 days; for acute otitis externa, may use 5 drops twice daily for 7 days.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | For children aged 1 year and older: same as adult dosing: 5 drops (0.5 mL) into affected ear(s) twice daily for 10-14 days. |
| Geriatric use | No specific dosage adjustment required; use with caution in elderly patients with pre-existing hearing loss or vestibular disorders. |
| 1st trimester | Avoid use due to potential risk of arthropathy in animal studies; alternative agents preferred. |
| 2nd trimester | Use only if clearly needed; no well-controlled human studies, but risk of cartilage damage considered low with short-term use. |
| 3rd trimester | Use only if clearly needed; theoretical risk of ototoxicity and cartilage damage in neonate. |
Clinical note
Comprehensive clinical and safety monograph for FLOXIN OTIC (FLOXIN OTIC).
| Placental transfer | Ofloxacin crosses the placenta, achieving fetal serum concentrations approximately 50-70% of maternal levels. |
| Breastfeeding | Ofloxacin is excreted into breast milk in small amounts. Use caution due to potential for adverse effects in nursing infants, such as diarrhea or candidiasis. Consider alternative agents if possible. |
■ FDA Black Box Warning
No FDA black box warning for FLOXIN OTIC. However, systemic fluoroquinolones have a boxed warning for tendinitis, tendon rupture, peripheral neuropathy, CNS effects, and exacerbation of myasthenia gravis; these warnings do not apply to otic use.
| Serious Effects |
History of hypersensitivity to ofloxacin or any fluoroquinoloneHistory of tendinitis or tendon rupture with fluoroquinolone useChildren under 1 year of age (systemic use) due to arthropathy riskPerforated tympanic membrane (otic use)
| Precautions | For otic use only; not for ophthalmic or systemic use, Discontinue if sensitization or irritation occurs, Prolonged use may result in overgrowth of non-susceptible organisms, including fungi, Avoid in patients with a known history of hypersensitivity to fluoroquinolones |
| Food/Dietary | No clinically significant food interactions. No dietary restrictions required. |
Loading safety data…
| Lactation Rating |
| L3 (Moderately Safe) |
| Teratogenic Risk | Otic administration results in negligible systemic absorption; therefore, fetal exposure is minimal. No teratogenic effects reported during any trimester. Animal studies show no evidence of harm at doses far exceeding clinical exposure. |
| Fetal Monitoring | No specific monitoring required due to minimal systemic absorption. |
| Fertility Effects | No effects on fertility anticipated due to negligible systemic absorption. |
| Clinical Pearls | FLOXIN OTIC (ofloxacin otic solution) is indicated for acute otitis externa (AOE) and acute otitis media (AOM) with tympanostomy tubes. It is the only otic fluoroquinolone approved for AOM with tubes. Avoid systemic absorption by ensuring the patient is not allergic to fluoroquinolones. Administer at room temperature to avoid vestibular stimulation. For AOE, the typical regimen is 5 drops twice daily for 7 days; for AOM with tubes, 5 drops twice daily for 10 days. Efficacy is comparable to neomycin/polymyxin B/hydrocortisone but without ototoxicity risk. |
| Patient Advice | Warm the bottle in your hands for 1-2 minutes before use to avoid dizziness. · Lie on your side with the affected ear up for 5 minutes after instilling drops. · Do not touch the dropper tip to any surface to prevent contamination. · Complete the full course of therapy even if symptoms improve. · Avoid getting water in the ear during treatment (use earplugs when showering). · Report any signs of allergic reaction (rash, itching, swelling) to your doctor. |